178 related articles for article (PubMed ID: 24322598)
21. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
22. Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.
Taylor VJ; Barnes PJ; Godwin SC; Bethune GC
Virchows Arch; 2021 Jul; 479(1):23-31. PubMed ID: 33527151
[TBL] [Abstract][Full Text] [Related]
23. [2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France].
Franchet C; Djerroudi L; Maran-Gonzalez A; Abramovici O; Antoine M; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Duprez-Paumier R; Fleury C; Ghnassia JP; Haudebourg J; Leroux A; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin YM; Roger P; Russ E; Tixier L; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
Ann Pathol; 2021 Nov; 41(6):507-520. PubMed ID: 34393014
[TBL] [Abstract][Full Text] [Related]
24. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
[TBL] [Abstract][Full Text] [Related]
25. Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Li A; Bai Q; Kong H; Zhou S; Lv H; Zhong S; Li M; Bi R; Zhou X; Yang W
Arch Pathol Lab Med; 2020 Sep; 144(9):1097-1107. PubMed ID: 32142367
[TBL] [Abstract][Full Text] [Related]
26. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
Gordian-Arroyo AM; Zynger DL; Tozbikian GH
Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
[TBL] [Abstract][Full Text] [Related]
27. Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category.
Pasricha S; Gupta G; Garg R; Sharma A; Gandhi JS; Durga G; Kamboj M; Grover S; Mehta A
Breast J; 2018 Jul; 24(4):468-472. PubMed ID: 29251392
[TBL] [Abstract][Full Text] [Related]
28. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
Ballinger TJ; Sanders ME; Abramson VG
Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
[TBL] [Abstract][Full Text] [Related]
29. Applying the New Guidelines of HER2 Testing in Breast Cancer.
Zhang H; Moisini I; Ajabnoor RM; Turner BM; Hicks DG
Curr Oncol Rep; 2020 Apr; 22(5):51. PubMed ID: 32346807
[TBL] [Abstract][Full Text] [Related]
30. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.
Kalemkerian GP; Narula N; Kennedy EB; Biermann WA; Donington J; Leighl NB; Lew M; Pantelas J; Ramalingam SS; Reck M; Saqi A; Simoff M; Singh N; Sundaram B
J Clin Oncol; 2018 Mar; 36(9):911-919. PubMed ID: 29401004
[TBL] [Abstract][Full Text] [Related]
31. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory.
Lin L; Sirohi D; Coleman JF; Gulbahce HE
Am J Clin Pathol; 2019 Sep; 152(4):479-485. PubMed ID: 31172196
[TBL] [Abstract][Full Text] [Related]
32. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
McLemore LE; Albarracin CT; Gruschkus SK; Bassett RL; Wu Y; Dhamne S; Yim I; Lin K; Bedrosian I; Sneige N; Chen H
Breast Cancer Res Treat; 2021 May; 187(1):95-104. PubMed ID: 33813685
[TBL] [Abstract][Full Text] [Related]
33. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.
Farshid G; Bilous M; Morey A; Fox S; Lakhani S; Loi S; Bell R; Spillane A
Pathology; 2019 Jun; 51(4):345-348. PubMed ID: 31076089
[TBL] [Abstract][Full Text] [Related]
34. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer.
Xu B; Shen J; Guo W; Zhao W; Zhuang Y; Wang L
Pathol Res Pract; 2019 Feb; 215(2):251-255. PubMed ID: 30420102
[TBL] [Abstract][Full Text] [Related]
35. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.
Advani PP; Crozier JA; Perez EA
Biomark Med; 2015; 9(1):35-49. PubMed ID: 25605454
[TBL] [Abstract][Full Text] [Related]
36. The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
Aapro M; De Laurentiis M; Rea D; Bargallo Rocha JE; Elizalde R; Landherr L; Linderholm B; Mamounas E; Markopoulos C; Neven P; Petrovsky A; Rouzier R; Smit V; Svedman C; Schneider D; Thomssen C; Martin M
Breast; 2017 Jun; 33():191-199. PubMed ID: 28441617
[TBL] [Abstract][Full Text] [Related]
37. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
[TBL] [Abstract][Full Text] [Related]
38. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers in the management of breast cancer: great expectations, hard times.
Bertelli G; Nelmes DJ; Al-Allak A
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):481-4. PubMed ID: 24220569
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer and genomic testing.
Liedtke C; Kolberg HC
Br J Surg; 2017 Jun; 104(7):799-801. PubMed ID: 28300277
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
